Soligenix Beheer

Beheer criteriumcontroles 2/4

De CEO Soligenix is Christopher Schaber, benoemd in Aug2006, heeft een ambtstermijn van 16.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 711.19K, bestaande uit 70.2% salaris en 29.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde € 16.11K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.9 jaar en 13.9 jaar.

Belangrijke informatie

Christopher Schaber

Algemeen directeur

US$711.2k

Totale compensatie

Percentage CEO-salaris	70.2%
Dienstverband CEO	16.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	8.9yrs
Gemiddelde ambtstermijn bestuur	13.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Christopher Schaber's beloning veranderd ten opzichte van Soligenix's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m
Sep 30 2017	n/a	n/a	-US$5m
Jun 30 2017	n/a	n/a	-US$6m
Mar 31 2017	n/a	n/a	-US$4m
Dec 31 2016	US$598k	US$435k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 711.19K ) Christopher } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Christopher is gestegen terwijl het bedrijf verliesgevend is.

CEO

Christopher Schaber (56 yo)

16.8yrs

Tenure

US$711,186

Compensatie

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Schaber	Chairman of the Board of Directors	16.8yrs	US$711.19k	0.20% € 16.1k
Jonathan Guarino	Senior VP	3.7yrs	US$355.35k	0.025% € 2.0k
Oreola Donini	Senior VP & Chief Scientific Officer	8.4yrs	US$364.24k	0% € 0
Richard Straube	Senior VP & Chief Medical Officer	9.3yrs	US$242.33k	0.018% € 1.4k

8.9yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DOA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christopher Schaber	Chairman of the Board of Directors	16.8yrs	US$711.19k	0.20% € 16.1k
Jerome Zeldis	Independent Director	11.9yrs	US$80.00k	0.052% € 4.1k
Gregory Lapointe	Independent Director	14.2yrs	US$87.50k	0.017% € 1.3k
Robert Rubin	Independent Director	13.6yrs	US$85.00k	0.010% € 785.2
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	geen gegevens	geen gegevens
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	geen gegevens	geen gegevens
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	geen gegevens	geen gegevens
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	geen gegevens	geen gegevens
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	geen gegevens	geen gegevens
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	geen gegevens	geen gegevens
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	geen gegevens	geen gegevens

13.9yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DOA zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).

Soligenix Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd